Medical Device Registration in India: How Are Authorized Representative Responsibilities Divided?

How Are Authorized Representative Responsibilities Divided for Medical Device Registration in India?

Under India's Medical Device Rules, 2017 and the CDSCO licensing framework, responsibility is divided between two parties: the foreign manufacturer retains full accountability for product safety, performance, clinical evidence and the technical file, while the Indian Authorized Agent (also referred to as the Authorized Representative, or AR) is the legally recognized in-country entity responsible for the application, correspondence with the regulator, import-related obligations, post-market surveillance liaison and adverse event reporting. The foreign manufacturer is typically required to obtain a Registration Certificate for its manufacturing site, while the Authorized Agent applies for and holds the Import Licence and acts as the CDSCO's point of contact for that licence. Because the split determines who controls the certificate, who triggers variations and who maintains the licence over time, it must be defined in a written agreement before filing rather than left to a commercial distribution contract.

Published: 2026-07-15 14:07  |  Updated: 2026-07-15 14:07

This FAQ addresses the practical questions that arise in international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Key Takeaways

• Before addressing how AR responsibilities are divided, confirm the target country, device risk class, applicable regulatory pathway and the existing documentation base.
• Then assess technical documentation, quality management system evidence, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance obligations.
• AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete dossiers or undefined authorization arrangements do not extend the project timeline.
• For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a gap assessment first, then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.
• Target-market registration typically affects the technical file, authorized representative, importer cooperation, label language, QMS evidence and subsequent change maintenance at the same time. Handling the project purely as a list of documents to submit tends to produce deficiency letters or rework in model coverage, evidence-chain consistency, label claims and certificate control.
• AIMEILI recommends planning this question within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation country by country.

Applicable Scenarios and Core Questions

Companies searching for how AR responsibilities are divided for India registration are usually not looking for a conceptual explanation. They need to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines become extended, and which issues could affect the launch plan. Behind this question there are typically several overlapping topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company intends to enter several GHWP member states, or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence and labelling, and then localize them according to each national regulatory requirement.

Registration Decision Logic

Companies should first confirm the intended purpose, mechanism of action, use environment, body contact type, duration of use, sterility, whether the device is active, and whether it contains software or has IVD characteristics. Only then can the risk class and submission pathway be determined. If the pathway is assessed incorrectly, all downstream translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a target-market project, the applicant entity and the boundary of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains the documentation for licence renewal. If these points are only handled vaguely in a commercial contract, market control can be affected later.

Documentation and Evidence

Typical documentation includes the device description, model and specification matrix, intended purpose, risk classification rationale, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The critical factor in documentation quality is not volume but consistency. IFU claims, the model coverage of test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use in the target market, not on how many documents have been uploaded.

Common Errors

The most frequent problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting a direct translation of domestic NMPA documentation without restructuring the evidence according to the target-market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling cover an insufficient scope.
• Selecting a local agent solely on the basis of sales cooperation, without defining regulatory responsibility, certificate control or post-market maintenance duties.
• Inconsistency between labels, IFUs, promotional material and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that each country requires separate preparation and both cost and timeline are multiplied.

Manufacturer Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix, and intended purpose statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English-language IFU.
• Confirm the duties, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Build a target-country gap assessment table identifying what must be re-tested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI advises manufacturers not to treat target-market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and better for subsequent changes and renewals than supplementing documentation country by country on an ad hoc basis.

From a project management perspective, three items should be controlled early: first, product classification and pathway determination; second, consistency of the documentation and evidence chain; third, the regulatory responsibility boundary of the local partner. If these three items are unclear, the project may still encounter repeated rounds of deficiency responses, agent communication and post-market maintenance even when the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a foundation, but it generally cannot be submitted as is. Companies must adjust the documentation structure, language, labelling, authorization documents and evidence chain to meet local regulatory requirements.

When is the best time to start a gap assessment?

Start it immediately after confirming the target markets and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent is typically involved in regulatory communication, variations, licence renewal and post-market incident handling. Unclear rights and responsibilities can affect certificate control and the stability of the market after approval.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project register that tracks the product list, model and specification matrix, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, clarifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and IFUs, clinical evaluation, risk management, performance verification and QMS certificates in particular must remain version-consistent.

• Confirm the target markets and product list.
• Complete risk classification and pathway determination.
• Build the documentation gap assessment table.
• Define local agent duties and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

QMS and Evidence Consistency

From a review perspective, QMS documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of the ISO 13485 certificate does not match the devices being registered, or if the manufacturing address, model specifications or IFU version do not align with the test reports, the company may be asked for supplementary explanation even when a large volume of documentation has been prepared.

Before submission, companies should create an evidence consistency checklist that maps product name, model and specification, intended purpose, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and QMS certificate item by item. This step appears basic but can noticeably reduce deficiency rates, particularly for projects filed simultaneously in several GHWP member states or covering multiple product families.

Localization and Agent Responsibility

Target-market registration projects usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market incident reporting, variation applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative details and after-sales contact information. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, rather than writing an isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean compliance work is finished. Companies must also maintain certificate validity, variation records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily at the approval stage but neglect post-market maintenance; when a manufacturing site change, model extension, IFU update or agent replacement later occurs, the certificate and commercial distribution can easily become disconnected.

AIMEILI recommends managing this question within an annual international registration plan: define target-market priorities first, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value lies not only in improving registration efficiency in a single country, but in enabling companies to build a repeatable overseas compliance capability and reduce the cost of starting documentation preparation from scratch each time they enter a new market.

Further Reading

Previous: How Should a Local Agent Be Selected for Medical Device Registration in India?

Next: Why Does the Medical Device Registration Timeline in India Become Extended?

Recommended reading:

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Does the Medical Device Registration Timeline in Brazil Become Extended?
• What Are the Common Reasons for Deficiency Letters in Brazil Medical Device Registration?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must a Registration Variation Be Filed for Medical Device Registration in Brazil?

Return to the FAQ Centre. News and insights. Contact AIMEILI.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI International Medical Device Registration Project Team.

Sourcing principle: official regulatory authorities, international organizations, standards bodies and public regulatory materials are prioritized; industry media and project experience are used only as supporting judgment.

Scope of application: this article supports preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target-country regulator, testing conclusions or legal advice.